Showing results (1701-1710 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|September 7, 2014
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistanceValeria Sero, Elisa Tavanti, Serena Vella, et al.Investigational New Drugs|April 1, 1989
Folinic acid modulation of fluorouracil: tissue kinetics of bolus administrationC P Spears, B G Gustavsson, R FrösingInvestigational New Drugs|October 26, 2014
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsC Narjoz, A Cessot, A Thomas-Schoemann, et al.Investigational New Drugs|November 9, 2013
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor modelChang Hoon Moon, Seung Ju Lee, Ho Yong Lee, et al.Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.Investigational New Drugs|January 16, 2018
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumorsGentry T King, Keith D Eaton, Brandon R Beagle, et al.Investigational New Drugs|November 3, 2017
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumorsRastislav Bahleda, Marie-Cécile Le Deley, Apexa Bernard, et al.Investigational New Drugs|January 1, 1986
Skin reactions induced by trimetrexate, an analog of methotrexateR B Weiss, W D James, W B Major, et al.Investigational New Drugs|March 9, 2018
A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of MedicineAkihiko Ozaki, Morihito Takita, Tetsuya TanimotoPageof 372